Wanmatong

产品中心

专家团队

新闻中心

乳腺癌筛查

女性乳腺癌筛查: 权威专家剖析四个关键点

需要做什么检查,怎么做,多少钱?
您的当前位置:首页 > 万马通学堂 > 乳腺癌筛查 > 正文

女性乳腺癌筛查: 权威专家剖析四个关键点

2019-05-24

原标题:女性乳腺癌筛查: 权威专家剖析四个关键点
美国医师协会(ACP)最新临床指南中,针对无症状、一般风险女性的乳腺癌筛查给出了七项指导原则。乳腺癌权威专家,Dr. Andrew M. Kaunitz为您剖析其中的关键点所在。
 
【英文原文】
Today I return to the persistently emotional topic of breast cancer screening. Recommendations from professional societies about screening in average-risk women vary with respect to starting age, stopping age, frequency of screening, and whether a clinical breast examination should be performed. 
This guidance statement from the American College of Physicians (ACP) assessed seven existing guidelines addressing breast cancer screening in a symptomatic, average-risk women.
 
Here are the ACP's four principal recommendations:
For women aged 40-49 years, clinicians should review pros and consof mammography, taking into account a woman's preferences. The ACP cautioned that for most women in this age group, harms from screening out weigh the benefits.
For women aged 50-74 years, clinicians should offer biennial mammograms.
Women aged 75 yearrs or older or those with a life expectancy of 10 years or less should discontinue screening.
Regardless of age, screening clinical breast examinations are not recommended.
The ACP noted that, overall, the magnitude of reduction of breast cancer mortality associated with mammography is small, a point they felt that most guidelines did not emphasize. In addition, looking at all age groups, mammography was not found to reduce all-cause mortality.
While mammography was consistently found to reduce breast cancer mortality in women aged 50-69 years, most reviewed studies failed to demonstrate a similar reduction among younger women.
All reviewed evidence found that women aged 39-49 years received the least benefit from screening with respect to deaths prevented. 
In addition, screening in this age group was not found to reduce the incidence of advanced breast cancer. 
In these younger women, the harms, including over-diagnosis, over-treatment, false-positive results, and unnecessary diagnostic testing  (as well as biopsies) out weighed the benefits of screening.
Tags:
  • 万马科技
  • GE医疗
  • 协和医院
  • 西京医院
  • 中山医院
  • 第二医院

Platform Link

万马科技(股票代码:300698)是一家集研发、生产、销售为一体的高新技术企业,亦是万马通母公司

GE 医疗集团隶属于GE(通用电气)公司,为全世界提供开创医疗护理新时代的革新性医疗技术和服务,同时也是万马通的战略合作伙伴。

北京协和医院是一所位于北京市东城区,集医疗、科研、教学为一体的大型综合医院,与万马通共同打造ABUS远程会诊中心。

西京医院坐落在美丽的古都西安,为第四军医大学第一附属医院,前身是1939年延安抗战岁月里诞生的中央医院,目前与万马通共同打造ABUS远程会诊中心。

中山大学肿瘤医院肿瘤防治中心已经发展成为全国规模最大、学术力量最雄厚的集医疗、教学、科研、预防于一体的肿瘤学医、教、研基地之一,目前与万马通共同打造ABUS远程会诊中心。

浙江大学医学院附属第二医院创建于1869年,是一所综合性医院,亦是被国家卫健委公布为首批肿瘤多学科诊疗试点医院。目前与万马通共同打造ABUS远程会诊中心。

Wechat

万马通科技微信服务号